Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Purging in B-Cell NHL
NCT00028665Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jun 2000
- Primary completion
- Mar 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in B-cell non-Hodgkin lymphoma (B-NHL) (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoints: Total CD34 cells at 12 months, T and B lymphocyte counts at 12 months and 2 more. Started Jun 2000; status: completed.
02
Drugs
rituximab
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT00028665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00028665.